







UNITED STATES PATENT AND TRADEMARK OFFICETCH CENTER 1600/2000

UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/780,438

02/09/2001

Xiaoyang Qi

CONFIRMATION NO. 7718

FORMALITIES LETTER

OC000000007350544

FROST BROWN TODD LLC 2200 PNC Center 201 East Fifth Street Cincinnati, OH 45202-4182



Date Mailed: 01/24/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.



Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 1 - ATTORNEY/APPLICANT COPY

.

07-22-07

PATENT

<u> FED STATES PATENT & TRADEMARK OFFICE</u>

In re application of:

Applicants

Xiaoyang Qi

: Paper No:

Serial No.

09/780,438

Group Art Unit:

1615

RECEIVED

MAR - 6 2002

TECH CENTER 1600/2900

Filed:

February 9, 2001

: Examiner:

For:

FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS

AND POLYPEPTIDES FOR APPLICATION TO TRANSMEMBRANE

DRUG DELIVERY SYSTEM

RESPONSE

THE ASSISTANT COMMISSIONER FOR PATENTS Washington, D.C. 20231

Dear Sir:

In response to the Office Action, dated January 24, 2002, please consider the following remarks.

Attached hereto, as requested by the Examiner, is the corrected sequence listing for the above patent application, revised to comply with 37 CFR 1.821 - 1.825. A computerreadable diskette, which contains the sequence listing in ASCII format is also enclosed, along with a written sequence listing which is identical to the electronic sequence listing. These sequence listings correspond to the sequence listings contained in the above-cited application and as such, no new matter is introduced as a result of these corrections.

Respectfully submitted,

XIAOYANG QI, PH.D.

Registration No. 45,558 Attorney for Applicant Telephone (513) 651-6865 FROST BROWN TODD, LLC 2200 PNC Center 201 East Fifth Street Cincinnati, Ohio 45202-4182

Dated: February 21, 2002

Serial No. 09/780,438



RECEIVED

MAR - 6 2002

TECH CENTER 1600/2900

I hereby certify that a copy of this correspondence is being deposited with the United States Postal Service as EXPRESS MAIL in an envelope addressed to The Assistant Commissioner of Patents, Washington, D.C. 20231 this day of John 2002.

CINlibrary/1151462.1